Clinical trials: Stage A Prostate Cancer
Prostate Cancer
Multimodality Phase II Study in Prostate Cancer
This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy…
- Trial name
- NCT00734851
- Testing
- Docetaxel, Sunitinib, EBXRT
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Solid Tumors, Advanced Triple Negative Breast Cancer
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
This is a Phase 1b/2a dose escalation and expansion, multi-center study to be conducted in 2 phases: Phase 1b Dose Escalation Part 1 (Doublet Therapy) Dose Escalation Part 2 (Triplet Therapy) Phase 2a Dose Expansion (Triplet…
- Conditions
- Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer
- Trial name
- NCT03861403
- Testing
- TRX518, Cyclophosphamide, Avelumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Leap Therapeutics, Inc.
Prostate Cancer
Using PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early Stage
The aim of the study is the evaluation of the possible role of PSMA PET-CT in early detection of prostate cancer, reducing rate of unnecessary prostate biopsies, and in cases of prostate cancer, correct staging of the disease and…
- Trial name
- NCT04116086
- Testing
- Prostate Biopsy Test
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Prostate Cancer
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months…
- Trial name
- NCT00669162
- Testing
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.
- Trial name
- BRP30 (NCT03862170)
- Testing
- Ciprofloxacin, Cefazolin
- Where
- Canada
- Volunteers
- 158 people
- Sponsor
- CR-CSSS Champlain-Charles-Le Moyne
Prostate Cancer
Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer
A single arm phase II study of SBRT for prostate cancer to primarily assess acute and late toxicity and secondarily PSA outcomes and quality of life measurements of an extreme hypofractionated regimen of 36.25Gy in 5 fractions…
- Trial name
- NCT02313298
- Testing
- Stereotactic Body Radiotherapy
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National Cancer Centre, Singapore
Advanced Solid Tumor, RAF Mutation
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation
- Trial name
- NCT06287463
- Testing
- DCC-3084
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Prostate Cancer
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
This proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a history of aggressive prostate cancer, in the tumor…
- Trial name
- PGV-Prostate (NCT05010200)
- Testing
- PGV-001, Poly-ICLC, CDX-301
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ashutosh Kumar Tewari
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Prostate Cancer, Breast Cancer
Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer
This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i)…
- Trial name
- SIESTA (NCT04543799)
- Testing
- polysomnography, actigraphy, questionnaires
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Breast Cancer, Colorectal Cancer
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond…
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00897793
- Testing
- venipuncture, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
This randomized phase II trial studies how well finasteride works in treating patients with stage II prostate cancer who are undergoing surgery. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT00438464
- Testing
- Finasteride, Prostatectomy, Laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 204 people
- Sponsor
- National Cancer Institute (NCI)
Hot Flashes, Prostate Cancer
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.
- Trial name
- NCT00005623
- Testing
- cyproterone acetate, quality-of-life assessment
- Where
- United States
- Sponsor
- Barr Laboratories
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT07288359
- Testing
- GVV858, Fulvestrant, Letrozole
- Where
- 16 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
The goal of this clinical trial is to compare the combination of Darolutamide with Radium-223 or placebo and the effects on radiological progression-free survival for patients with Metastatic Castration-Sensitive Prostrate Cancer…
- Trial name
- CARE (NCT05771896)
- Testing
- Darolutamide, Radium-223
- Sponsor
- GenesisCare USA
Prostate Cancer
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical…
- Trial name
- NCT02923180
- Testing
- Enoblituzumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with…
- Trial name
- NCT01054079
- Testing
- laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
LDR vs. HDR Brachytherapy for Prostate Cancer
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy.
- Trial name
- LDR/HDRmono (NCT03426748)
- Testing
- Low dose rate prostate brachytherapy, High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Prostate Cancer Metastatic
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
A proportion of prostate cancer (PCa) patients develop relapse following curative local treatment. Regional nodal recurrence is an emerging clinical situation since the introduction of new molecular imaging methods in the…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Cancer
- Trial name
- STORM (NCT03569241)
- Testing
- whole pelvic radiotherapy, metastasis-directed treatment, salvage Lymph Node Dissection
- Where
- 29 sites in Australia, Belgium and 4 more
- Volunteers
- 196 people
- Sponsor
- University Hospital, Ghent
Castration Resistant Prostate Cancer
OGX-427 in Castration Resistant Prostate Cancer Patients
This study is being offered to patients who have castrate-resistant (also known as hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the prostate area to other parts of the body or has recurred in…
- Trial name
- NCT01120470
- Testing
- OGX-427, Prednisone
- Where
- 6 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- British Columbia Cancer Agency